Press release
Global Empagliflozin, Dapagliflozin And Canagliflozin Market Outlook 2025-2034: Trends, Innovations, And Future Outlook
Empagliflozin, Dapagliflozin And Canagliflozin Market
What Is the Empagliflozin, Dapagliflozin And Canagliflozin Market Size and Projected Growth Rate?
The empagliflozin, dapagliflozin and canagliflozin market size has grown steadily in recent years. It will grow from $9.64 billion in 2024 to $9.94 billion in 2025 at a compound annual growth rate (CAGR) of 3.1%. The growth in the historic period can be attributed to the increase in the prevalence of type 2 diabetes globally, increased awareness about the benefits of SGLT2 inhibitors, growth in the elderly population, growth in the prevalence of obesity, and increase in focus on personalized medicine.
The empagliflozin, dapagliflozin, and canagliflozin market is expected to see steady growth, projected to reach $11.06 billion by 2029, at a compound annual growth rate (CAGR) of 2.7%. Growth drivers include the increasing demand for oral diabetes medications, higher investments in diabetes research, rising healthcare expenditures, greater awareness and diagnosis of pre-diabetes, and the shift toward combination therapies. Key trends include advancements in drug development, combination therapies, telehealth, health data analytics, and data security.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18350
What Are the Major Segments in the Empagliflozin, Dapagliflozin And Canagliflozin Market?
The empagliflozin, dapagliflozin and canagliflozin market covered in this report is segmented -
1) By Type: Empagliflozin, Dapagliflozin, Canagliflozin
2) By Application: Application I, Application II, Application III, Application IV
3) By Channel: Hospital, Pharmacy
Subsegments:
1) Empagliflozin: 10 Mg, 25 Mg, 50 Mg
2) Dapagliflozin: 5 Mg, 10 Mg
3) Canagliflozin: 100 Mg, 300 Mg
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18350&type=smp
What Are The Driving Empagliflozin, Dapagliflozin And Canagliflozin Market Evolution?
The increasing prevalence of diabetes is expected to drive the growth of the empagliflozin, dapagliflozin, and canagliflozin market. These medications are used in the treatment of diabetes by inhibiting SGLT2 in the kidneys, thereby helping to lower blood sugar levels. As diabetes rates rise due to factors such as unhealthy diets, sedentary lifestyles, and aging populations, the demand for these treatments is expected to continue growing. A report from the UK's National Health Service highlighted an alarming increase in diabetes cases, further underscoring the growing need for SGLT2 inhibitors.
Which Firms Dominate The Empagliflozin, Dapagliflozin And Canagliflozin Market Segments?
Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., MSN Laboratories Private Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd.
What Empagliflozin, Dapagliflozin And Canagliflozin Market Trends Are Gaining Traction Across Different Segments?
Leading companies in the sector of empagliflozin, dapagliflozin, and canagliflozin markets are concentrating on development of revolutionary products like pediatric type-2 diabetes treatment, allowing them to cater to a wider range of patient demographics and broaden their scope in the diabetes care market. The approach to treating pediatric Type-2 diabetes involves controlling blood sugar levels through changes in lifestyle, the use of medications and occasionally, insulin therapy specially designed for children and young adolescents. For example, AstraZeneca, a prominent pharmaceutical company from the UK, announced in June 2024, that Farxiga (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) for enhancing glycemic control in pediatric patients who are 10 years old and above, diagnosed with type 2 diabetes. This approval came on the back of positive results attained from the T2NOW Phase III clinical trial, which is one of the most comprehensive pediatric type-2 diabetes trials so far, showcasing that Farxiga considerably lowered HbA1c levels when compared to a placebo. The safety profile of Farxiga in pediatrics mirrors that noted in adults with type-2 diabetes. This approval marks an essential landmark, considering that oral treatment options for Pediatric type-2 diabetes were limited till now. Moreover, it emphasizes AstraZeneca's dedication towards developing leading-edge treatments in the sectors of cardiovascular, renal, and metabolic diseases.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/empagliflozin-dapagliflozin-and-canagliflozin-global-market-report
Which Is The Largest Region In The Empagliflozin, Dapagliflozin And Canagliflozin Market?
North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2024. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Empagliflozin, Dapagliflozin And Canagliflozin Market?
2. What is the CAGR expected in the Empagliflozin, Dapagliflozin And Canagliflozin Market?
3. What Are the Key Innovations Transforming the Empagliflozin, Dapagliflozin And Canagliflozin Industry?
4. Which Region Is Leading the Empagliflozin, Dapagliflozin And Canagliflozin Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Empagliflozin, Dapagliflozin And Canagliflozin Market Outlook 2025-2034: Trends, Innovations, And Future Outlook here
News-ID: 4037020 • Views: …
More Releases from The Business Research Company
Foam Tape Industry to Achieve $14.62 Billion Growth by 2029
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
How Will the Foam Tape Market Grow by 2025 in Terms of Size and Growth?
In recent times, there has been significant growth in the market size for foam tape. It is projected to escalate from $10.02 billion in 2024 to $10.77 billion in 2025, demonstrating a compound annual growth rate (CAGR)…
Continuous Positive Airway Pressure (CPAP) Mask Market Expansion Outlook: $3.85 …
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
What Is the Projected CAGR for the Continuous Positive Airway Pressure (CPAP) Mask Market from 2024 to 2025?
In recent times, the market size of the continuous positive airway pressure (cpap) mask has seen robust growth. The market is projected to rise from $2.83 billion in 2024 to $3 billion in 2025,…
Alkyd Coating Market to Record 7.5% CAGR Growth Through 2029 | Global Analysis R …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Alkyd Coating Market Outlook: How is the Market Expected to Grow by 2025?
The market size of alkyd coatings has experienced significant growth in the past few years. The market is projected to expand from $25.13 billion in 2024 to $26.74 billion in 2025, exhibiting a compound annual growth rate…
Water Free Skincare Market Analysis: $22.5 Billion by 2029 With a CAGR of 7%
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
Water Free Skincare Market Value Projection: How Much Will the Market Size by 2025?
The market size of waterless skincare has experienced a robust increase in recent years. The expected growth is from $15.96 billion in 2024 to $17.15 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%.…
More Releases for Empagliflozin
Top Market Shifts Transforming the Empagliflozin, Dapagliflozin And Canagliflozi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Empagliflozin, Dapagliflozin And Canagliflozin Market Through 2025?
In recent times, the market size for empagliflozin, dapagliflozin, and canagliflozin has consistently expanded. Projected growth suggests an increase from $9.64 billion in 2024 to $9.94 billion in 2025, marking a compound annual growth rate…
Empagliflozin Impurity Standards: Ensuring Uncompromised Drug Quality with Preci …
Empagliflozin, a widely prescribed medication for managing Type 2 diabetes, has revolutionized the approach to treatment by enabling better glycemic control and reducing cardiovascular risks. As its demand grows, so does the need for impeccable quality standards to ensure its efficacy and safety for patients worldwide. Integral to achieving this is the availability of well-characterized impurity standards, which form the cornerstone for rigorous quality testing.
To meet these precise requirements, Empagliflozin…
Lizhuo Pharmaceutical Technology: Empagliflozin Intermediate 3 CAS NO. 1279691-3 …
Product Name:Empagliflozin Intermediate 3
Image: https://www.abnewswire.com/upload/2025/02/244d490e8e67be1fc6fd489f30405e07.jpg
CAS NO.:1279691-36-9
Synonyms:
Empagliflozin N-1;
(2S,3R,4S,5S,6R)-2-(3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)-4-chlorophenyl)-tetrahydro-6-(hydroxyMethyl)-2-Methoxy-2H-pyran-3,4,5-triol;
Methyl 1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]Methyl]phenyl]-alpha-D-glucopyranoside;
Related Categories:Empagliflozin intermediates; pharmaceutical raw materials; pharmaceutical intermediates; organic intermediates.
Appearance: White to Off-White solid
Purity: 98%
Application: Empagliflozin intermediates;pharmaceutical intermediate
Supply Ability
Empagliflozin Intermediate3 CAS NO.1279691-36-9 is our regularly production product, whether you need small sample or a large cargo of more than tonnage, our company can supply it formally
If you are interested in Empagliflozin Intermediate3 CAS NO.1279691-36-9, feel freely contact us please, and we will provide…
Empagliflozin, Dapagliflozin And Canagliflozin Market Size, Share Analysis And T …
The new report published by The Business Research Company, titled Empagliflozin, Dapagliflozin And Canagliflozin Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the empagliflozin, dapagliflozin and canagliflozin market size has grown steadily in recent years. It will grow from…
Empagliflozin, Dapagliflozin and Canagliflozin Market Research Report 2023: …
Empagliflozin, Dapagliflozin and Canagliflozin are three main types of SGLT-2 inhibitors.
Global Empagliflozin, Dapagliflozin and Canagliflozin Market: Driven factors and Restrictions factors
The research report encompasses a comprehensive analysis of the factors that affect the growth of the market. It includes an evaluation of trends, restraints, and drivers that influence the market positively or negatively. The report also outlines the potential impact of different segments and applications on the market in the…
Empagliflozin Tablets Market Opportunities and Growth Challenges Report 2022-203 …
Global Empagliflozin Tablets Market 2022-2028 - Global Industry Size, Supply Analysis, Price Analysis, Consumption and Production, Supplier and Cost Structure Analysis
Empagliflozin Tablets Market Overview
The recent market intelligence study by the research analysts at Market Business Insights (MBI) takes a deep dive into inner operations of the global Empagliflozin Tablets Market. It thoroughly examines the market landscape to give the readers an accurate insight into the current, as well as the…
